91 related articles for article (PubMed ID: 25730130)
1. A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.
Milite C; Feoli A; Sasaki K; La Pietra V; Balzano AL; Marinelli L; Mai A; Novellino E; Castellano S; Tosco A; Sbardella G
J Med Chem; 2015 Mar; 58(6):2779-98. PubMed ID: 25730130
[TBL] [Abstract][Full Text] [Related]
2. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
4. Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.
Sbardella G; Castellano S; Vicidomini C; Rotili D; Nebbioso A; Miceli M; Altucci L; Mai A
Bioorg Med Chem Lett; 2008 May; 18(9):2788-92. PubMed ID: 18434144
[TBL] [Abstract][Full Text] [Related]
5. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.
Shirakawa K; Wang L; Man N; Maksimoska J; Sorum AW; Lim HW; Lee IS; Shimazu T; Newman JC; Schröder S; Ott M; Marmorstein R; Meier J; Nimer S; Verdin E
Elife; 2016 May; 5():. PubMed ID: 27244239
[TBL] [Abstract][Full Text] [Related]
6. CPTH6, a thiazole derivative, induces histone hypoacetylation and apoptosis in human leukemia cells.
Trisciuoglio D; Ragazzoni Y; Pelosi A; Desideri M; Carradori S; Gabellini C; Maresca G; Nescatelli R; Secci D; Bolasco A; Bizzarri B; Cavaliere C; D'Agnano I; Filetici P; Ricci-Vitiani L; Rizzo MG; Del Bufalo D
Clin Cancer Res; 2012 Jan; 18(2):475-86. PubMed ID: 22068659
[TBL] [Abstract][Full Text] [Related]
7. Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4.
Henry RA; Kuo YM; Andrews AJ
Biochemistry; 2013 Aug; 52(34):5746-59. PubMed ID: 23862699
[TBL] [Abstract][Full Text] [Related]
8. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
10. Identification of structural features of 2-alkylidene-1,3-dicarbonyl derivatives that induce inhibition and/or activation of histone acetyltransferases KAT3B/p300 and KAT2B/PCAF.
Castellano S; Milite C; Feoli A; Viviano M; Mai A; Novellino E; Tosco A; Sbardella G
ChemMedChem; 2015 Jan; 10(1):144-57. PubMed ID: 25333655
[TBL] [Abstract][Full Text] [Related]
11. Histone acetyl transferases as emerging drug targets.
Dekker FJ; Haisma HJ
Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
[TBL] [Abstract][Full Text] [Related]
12. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
13. Use of histone deacetylase inhibitors to examine the roles of bromodomain and histone acetylation in p300-dependent gene expression.
Chen J; Li Q
Methods Mol Biol; 2013; 977():353-7. PubMed ID: 23436376
[TBL] [Abstract][Full Text] [Related]
14. Quinoline-based p300 histone acetyltransferase inhibitors with pro-apoptotic activity in human leukemia U937 cells.
Lenoci A; Tomassi S; Conte M; Benedetti R; Rodriguez V; Carradori S; Secci D; Castellano S; Sbardella G; Filetici P; Novellino E; Altucci L; Rotili D; Mai A
ChemMedChem; 2014 Mar; 9(3):542-8. PubMed ID: 24504685
[TBL] [Abstract][Full Text] [Related]
15. [Experiment study of PHI on histone methylation and acetylation in Molt-4 cells].
Huang YQ; Ma XD; Zhen RJ; Chiao JW; Liu DL
Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):612-5. PubMed ID: 18246819
[TBL] [Abstract][Full Text] [Related]
16. Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases.
Mai A; Rotili D; Tarantino D; Nebbioso A; Castellano S; Sbardella G; Tini M; Altucci L
Bioorg Med Chem Lett; 2009 Feb; 19(4):1132-5. PubMed ID: 19144517
[TBL] [Abstract][Full Text] [Related]
17. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
Kang J; Chen J; Shi Y; Jia J; Zhang Y
Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
[TBL] [Abstract][Full Text] [Related]
18. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
[TBL] [Abstract][Full Text] [Related]
19. Probing p300/CBP associated factor (PCAF)-dependent pathways with a small molecule inhibitor.
Modak R; Basha J; Bharathy N; Maity K; Mizar P; Bhat AV; Vasudevan M; Rao VK; Kok WK; Natesh N; Taneja R; Kundu TK
ACS Chem Biol; 2013; 8(6):1311-23. PubMed ID: 23570531
[TBL] [Abstract][Full Text] [Related]
20. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
